

January 08, 2026

To,
The Manager,
Dept. of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001

Dear Sir/Madam,

Subject : Subscription to Convertible Equity Warrants of M/s. Virinchi Limited issued on preferential basis – Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Scrip Code : 511509

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that Vivo Bio Tech Limited has subscribed to 86,00,000 (Eighty Six Lakh only) Convertible Equity Warrants issued by Virinchi Limited on a preferential basis.

The said subscription has been made pursuant to the approval accorded by the shareholders of Virinchi Limited at its Extra-Ordinary General Meeting held on Saturday, November 15, 2025 and pursuant to the in-principle approval given by BSE vide their letter LOD/PREF/KS/FIP/1456/2025-26 dated December 31, 2025; and by NSE vide their letter NSE/LIST/51564 dated December 31, 2025. The Convertible Equity Warrants have been subscribed at an issue price of Rs. 28/- per Warrant (Face Value of Rs. 10/- and Premium of Rs. 18/- per Warrant). An amount equivalent to 25% of the issue price, i.e., Rs. 7/- per Warrant, aggregating to Rs. 6,02,00,000/- (Rupees Six Crore Two Lakh only), has been paid by Vivo Bio Tech Limited towards subscription of the said Warrants.

Each Convertible Equity Warrant is convertible into one fully paid-up equity share of Virinchi Limited upon payment of the balance 75% of the issue price, i.e., Rs. 21/- per Warrant, within the period prescribed under the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Kindly take the above information on your record.

Thanking You,

For Vivo Bio Tech Limited

A V Kiran
Company Secretary